临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Ibuprofen (NSC 256857)
中文名称:布洛芬
CAS号:15687-27-1
分子式: C13H18O2 分子量: 206.28
产品形式: free base
研发状态: Recruiting
研发用途: Pain Postoperative
研究机构: B.P. Koirala Institute of Health Sciences
研发日期: August 10 2023
研发阶段: Phase 4
Ibuprofen (NSC 256857, Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.
Cephalexin
中文名称:头孢氨苄
CAS号:15686-71-2
分子式: C16H17N3O4S 分子量: 347.39
产品形式: free base
研发状态: Enrolling by invitation
研发用途: Neonatal Infection
研究机构: University of Colorado Denver
研发日期: July 14 2021
研发阶段: Phase 1
Cephalexin (Cefalexin) is an antibiotic that can treat a number of bacterial infections.
Sulpiride
中文名称:舒必利
CAS号:15676-16-1
分子式: C15H23N3O4S 分子量: 341.43
产品形式: free base
研发状态: Completed
研发用途: Healthy
研究机构: Damanhour University
研发日期: Jan-13
研发阶段: Not Applicable
Sulpiride (Dolmatil, Dobren, Sulpyrid, Aiglonyl, Dogmatil) is a dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid.
Sodium butyrate
中文名称:丁酸钠
CAS号:156-54-7
分子式: C4H7NaO2 分子量: 110.09
产品形式: Sodium Salt
研发状态: Completed
研发用途: Shigellosis
研究机构: International Centre for Diarrhoeal Disease Research Bangladesh; Swedish International Development Cooperation Agency (SIDA); Karolinska Institutet
研发日期: Jan-05
研发阶段: Phase 2
Sodium butyrate (NaB, Butanoic acid sodium salt), sodium salt of butyric acid, is a histone deacetylase inhibitor and competitively binds to the zinc sites of class I and II histone deacetylases (HDACs). Sodium butyrate (NaB) inhibits cell cycle progression, promotes differentiation, and induces apoptosis and autophagy in several types of cancer cells.
Alvimopan
中文名称:爱维莫潘
CAS号:156053-89-3
分子式: C25H32N2O4 分子量: 424.53
产品形式: Free Base
研发状态: Terminated
研发用途: Post Operative Ileus
研究机构: University of Puerto Rico; Merck Sharp & Dohme LLC
研发日期: September 1 2017
研发阶段: Phase 4
Alvimopan (LY 246736, ADL 8-2698) is a potent, relatively nonselective opioid antagonist with Ki values of 0.77, 4.4, and 40 nM for the μ, δ, and κ opioid receptors, respectively, displaying >100-fold selectivity over other aminergic G-protein-coupled receptors.
Avitinib (AC0010)
中文名称:艾维替尼
CAS号:1557267-42-1
分子式: C26H26FN7O2 分子量: 487.53
产品形式: Free Base
研发状态: Unknown status
研发用途: B-cell Lymphoma
研究机构: Hangzhou ACEA Pharmaceutical Research Co. Ltd.
研发日期: March 17 2017
研发阶段: Phase 1
Avitinib (AC0010) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type EGFR (IC50 value, 7.68 nM). It has comparable anti-tumor activity and tolerated toxicity.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
